Gates Capital Management Inc. boosted its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 3.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 905,830 shares of the company's stock after purchasing an additional 27,660 shares during the period. DaVita comprises about 2.2% of Gates Capital Management Inc.'s portfolio, making the stock its 14th largest holding. Gates Capital Management Inc. owned 0.99% of DaVita worth $94,895,000 at the end of the most recent quarter.
A number of other hedge funds have also added to or reduced their stakes in DVA. 8 Knots Management LLC acquired a new stake in DaVita in the fourth quarter valued at $89,504,000. Cubist Systematic Strategies LLC lifted its stake in DaVita by 156.7% in the fourth quarter. Cubist Systematic Strategies LLC now owns 136,265 shares of the company's stock valued at $14,275,000 after acquiring an additional 83,183 shares during the last quarter. Bellevue Group AG acquired a new stake in DaVita in the fourth quarter valued at $398,000. Doma Perpetual Capital Management LLC acquired a new stake in DaVita in the fourth quarter valued at $53,076,000. Finally, Connectus Wealth LLC acquired a new stake in DaVita in the fourth quarter valued at $210,000. Institutional investors own 90.12% of the company's stock.
DaVita Stock Performance
Shares of NYSE DVA traded down $0.53 during mid-day trading on Thursday, reaching $142.16. 551,277 shares of the company were exchanged, compared to its average volume of 837,975. The stock has a market capitalization of $12.47 billion, a P/E ratio of 16.15, a P/E/G ratio of 1.08 and a beta of 0.96. The company has a quick ratio of 1.37, a current ratio of 1.43 and a debt-to-equity ratio of 7.95. The company's 50-day simple moving average is $137.11 and its 200-day simple moving average is $123.59. DaVita Inc. has a twelve month low of $71.51 and a twelve month high of $147.93.
DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings results on Thursday, May 2nd. The company reported $2.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.95 by $0.43. The company had revenue of $3.07 billion for the quarter, compared to analyst estimates of $3.03 billion. DaVita had a net margin of 6.61% and a return on equity of 68.52%. The firm's revenue was up 6.9% on a year-over-year basis. During the same period in the previous year, the firm posted $1.58 EPS. As a group, research analysts predict that DaVita Inc. will post 9.62 earnings per share for the current year.
Insider Buying and Selling
In related news, Director Barbara J. Desoer sold 5,030 shares of DaVita stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $138.81, for a total transaction of $698,214.30. Following the sale, the director now directly owns 10,954 shares in the company, valued at approximately $1,520,524.74. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 2.00% of the stock is owned by corporate insiders.
Wall Street Analyst Weigh In
A number of analysts have commented on DVA shares. UBS Group increased their price target on shares of DaVita from $113.00 to $134.00 and gave the company a "buy" rating in a research note on Wednesday, February 14th. StockNews.com cut shares of DaVita from a "strong-buy" rating to a "buy" rating in a research note on Saturday, June 8th. Truist Financial raised their target price on shares of DaVita from $135.00 to $150.00 and gave the stock a "hold" rating in a research note on Wednesday, May 15th. Finally, Barclays raised their target price on shares of DaVita from $133.00 to $150.00 and gave the stock an "equal weight" rating in a research note on Monday, May 6th. Two research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, DaVita has a consensus rating of "Moderate Buy" and an average price target of $144.67.
Read Our Latest Stock Analysis on DVA
DaVita Company Profile
(Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Further Reading
- Five stocks we like better than DaVita
- How to Invest in Insurance Companies: A Guide
- 3 Healthcare Dividend Stocks to Buy
- The FOMC Decision Means Higher Prices for Stocks This Summer
- Investing in Travel Stocks Benefits
- Here's Why Analysts Boosted Walmart Stock's Valuation
→ Musk’s new company could top a trillion? (From Paradigm Press) (Ad)
Should you invest $1,000 in DaVita right now?
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
10 Best Cheap Stocks to Buy Now
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
